News | Heart Failure | July 13, 2017

Vest Wearable Monitor May Reduce Heart Failure Readmissions

The SensiVest uses radar technology to detect the exact amount of fluid in the lungs

monitoring a heart failure patient's chest fluid buildup with remote monitoring using the SensiVest

A heart failure patient wearing the SensiVest remote monitoring system for a two-minute a day assessment. 


July 13, 2017 — About 5.7 million adults in the U.S. suffer from heart failure, and because of a dangerous buildup of fluid in their lungs, more than half of those patients end up back in the hospital within six months. But researchers say a high-tech vest that is entering U.S. trials may help doctors monitor a heart patient’s symptoms remotely, which may prevent the need for rehospitalization.

The SMILE Trial (Sensible Medical Innovations Lung fLuid status monitor allows rEducing readmission rate of heart failure patients study) will look at the efficacy of the SensiVest, a product developed by Sensible Medical Innovations, headquartered in Israel. The system is comprised of a wearable vest containing two embedded sensors, one in front and one behind the patient, and a bedside console. 

“The major cause of readmission for heart failure patients is excess fluid in the lungs,” said William Abraham, M.D., FACC, director of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, who is leading a randomized, clinical trial of the vest. “The vest allows us to see when the lungs are trending toward being too wet so a patient’s medication can be adjusted before they even notice any symptoms.”

Watch a VIDEO showing how the vest works and to hear more about it from Abraham.

The vest uses radar technology to “see through” the chest and accurately detect the amount of fluid in the lungs. A patient wears the vest for just 90 seconds a day and the information collected is automatically uploaded to a cloud server. The patient’s cardiologist can review the data to determine if any treatment adjustments need to be made to restore the lungs to healthy fluid levels.

“This technology gives us absolute and actionable data of lung fluid content that we can use to keep patients healthy and out of the hospital,” Abraham said. “The fact that it is completely non-invasive and takes less than two minutes a day to use, allows patients to live a better quality of life with heart failure.”

A study initially conducted in Israel reported that hospital readmission rates were reduced by 87 percent for patients who were part of the study. 

The vest uses the same technology used by the military for things like “seeing through” walls before entering a building or searching through rubble for survivors after a natural disaster.

Watch a VIDEO discussion with Abraham on several new technologies to treat HF and reduce heart failure readmissions from TCT 2016.

Read the article "Reducing Heart Failure Readmissions."


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now